EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy

By sjmartinez • October 30, 2022

Kang JJ, Ko A, Kil SH, Clair JM, Shin DS, Wang MB, Srivatsan ES. EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy. Biochim Biophys Acta Rev Cancer. 2022 Oct 26:188827. doi: 10.1016/j.bbcan.2022.188827. Epub ahead of print. PMID: 36309124.

Tags: Epidermal growth factor receptor, Head and neck cancer, Head and neck squamous cell carcinoma, Hematology/Oncology, immunotherapy, Monoclonal antibodies, Publications, Receptor tyrosine kinase, Small molecular inhibitors, Veterans Administration

Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm

De Botton S, Récher C, Cortes J, Curti A, Fenaux P, Peterlin P, Pigneux A, Yee K, Wei A, Mims A, Schiller G, Chao MM,[...]

Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now

Shore N, Nielsen SM, Esplin ED, Antonarakis ES, Barata PC, Beer TM, Beltran H, Bryce A, Cookson MS, Crawford ED, Dorff TB, George DJ, Heath[...]

Retrospective Study of CD20 Expression Loss in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Marshalek JP, Qing X, Dragan M, Tomassetti S. Retrospective Study of CD20 Expression Loss in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. J Hematol. 2024 Dec;13(6):268-277.[...]